Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for millions of kids: easier treatment for a devastating parasitic disease

NCT ID NCT06698510

Disease control Sponsor: Peter Steinmann Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to see how well a new, child-friendly version of the drug praziquantel works to control schistosomiasis in preschool-aged children (2 to 5 years old) in parts of Kenya, Côte d'Ivoire, and Uganda. About 18,500 children will receive the medicine through existing public health programs. The goal is to find the best way to deliver the drug to this age group, who are often missed in current treatment campaigns.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 18,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

* Study population receiving intervention: All eligible preschool-aged children (2-5 years) from pre-selected study areas for small-scale implementation present at the day of the treatment campaign, will be accessed and treated with arpraziquantel by one of the two selected platforms depending on the assignment of the area. * Study population of post-distribution social science study: Subsamples of parents of preschool-aged children of the respective implementation areas, community stakeholders involved in social mobilization and distribution, health workers and programmatic staff involved in training, social mobilization and distribution.

Ages

24 to 59 months

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Living in the designated implementation area since at least 6 months * Aged between 24 - 59 months * Informed consent available * No acute or chronic illness and/or inability to take oral medication * No reported history of seizures * No known allergic response to praziquantel

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schistosomiasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

schistosomiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Schistosomiasis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • African Institute for Health and Development (AIHD)

    NOT_YET_RECRUITING

    Nairobi, Kenya

  • Kenya Medical Research Institute (KEMRI), Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC)

    NOT_YET_RECRUITING

    Nairobi, Kenya

  • Makerere University, Department of Sociology and Anthropology

    NOT_YET_RECRUITING

    Kampala, Uganda

  • Programme National de Lutte Contre les Maladies Tropicales Négligées à Chimiothérapie Préventive (PNLMTN-CP), Ministère de la Santé, de l'Hygiène Publique et de la Couverture Maladie Universelle (MSHPCMU)

    RECRUITING

    Abidjan, Côte d’Ivoire

  • Université Félix Hophouët-Boigny (UFHB), Département de sociologie

    RECRUITING

    Abidjan, Côte d’Ivoire

  • Université Félix Hophouët-Boigny (UFHB), UFR Biosciences

    RECRUITING

    Abidjan, Côte d’Ivoire

  • Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health

    NOT_YET_RECRUITING

    Kampala, Uganda

More trials for these conditions

Other studies related to the condition(s) this trial covers.